Genmab A/S
GMAB · NasdaqPharmaceutical Preparations · Reports in DKK
Net income was DKK 7.8B.
Last 5 fiscal years
Revenue and net income
Income statement
| Fiscal year | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|
| Revenue | DKK 2.4B | DKK 3B | DKK 5.4B | – | – |
| Research & development | DKK 874M | DKK 1.4B | DKK 2.4B | – | – |
| Operating income | DKK 1.3B | DKK 1.4B | DKK 2.6B | – | – |
| Interest expense | DKK 352M | DKK 11M | DKK 7M | – | – |
| Pre-tax income | DKK 1.1B | DKK 1.6B | DKK 2.9B | – | – |
| Income tax | −DKK 40M | DKK 140M | DKK 693M | – | – |
| Net income | DKK 1.1B | DKK 1.5B | DKK 2.2B | DKK 4.4B | DKK 7.8B |
Balance sheet
| Fiscal year | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|
| Cash & equivalents | DKK 1.3B | DKK 533M | DKK 3.6B | – | – |
| Receivables | – | DKK 1.3B | DKK 3B | – | – |
| Current assets | – | DKK 7.4B | DKK 14B | – | – |
| Net PP&E | – | DKK 162M | DKK 237M | – | – |
| Total assets | – | DKK 8.5B | DKK 15.1B | DKK 35.3B | DKK 45.8B |
| Current liabilities | – | DKK 444M | DKK 938M | – | – |
| Total liabilities | – | DKK 447M | DKK 1.1B | DKK 3.7B | DKK 9.1B |
| Shareholders' equity | DKK 6.3B | DKK 8B | DKK 14B | DKK 31.6B | DKK 36.7B |
Cash flow
| Fiscal year | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|
| Operating cash flow | DKK 1.6B | DKK 1B | DKK 1.3B | DKK 7.4B | DKK 7.8B |
| Capital expenditure | DKK 89M | DKK 72M | DKK 79M | – | – |
| Free cash flow | DKK 1.5B | DKK 943M | DKK 1.2B | – | – |
Key ratios
| Fiscal year | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 27.9% | 77.4% | – | – |
| Operating income growth (YoY) | – | 2.7% | 91.2% | – | – |
| Operating margin | 56.8% | 45.6% | 49.2% | – | – |
| Net margin | 46.7% | 48.7% | 40.4% | – | – |
| Return on equityBlank when equity is negative | 17.6% | 18.4% | 15.4% | 13.8% | 21.4% |
| ROCEEBIT ÷ (assets − current liabilities) | – | 17.2% | 18.6% | – | – |
| Free cash flow margin | 63.4% | 31.2% | 23.2% | – | – |
| Cash conversion (CFO ÷ net income) | 1.44x | 0.69x | 0.61x | 1.70x | 0.99x |
| Receivable days | – | 160 | 203 | – | – |
| Interest cover | 3.82x | 125x | 377x | – | – |
| Current ratio | – | 16.7x | 14.9x | – | – |
More in Pharmaceutical Preparations
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.